HK1162488A1 - Stem cell cultures - Google Patents
Stem cell culturesInfo
- Publication number
- HK1162488A1 HK1162488A1 HK12102882.3A HK12102882A HK1162488A1 HK 1162488 A1 HK1162488 A1 HK 1162488A1 HK 12102882 A HK12102882 A HK 12102882A HK 1162488 A1 HK1162488 A1 HK 1162488A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- stem cell
- cell cultures
- cultures
- stem
- cell
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20080808P | 2008-12-03 | 2008-12-03 | |
PCT/US2009/066554 WO2010065721A1 (en) | 2008-12-03 | 2009-12-03 | Stem cell cultures |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1162488A1 true HK1162488A1 (en) | 2012-08-31 |
Family
ID=42233609
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12101691.6A HK1161590A1 (en) | 2008-12-03 | 2012-02-21 | Stem cell cultures |
HK12102882.3A HK1162488A1 (en) | 2008-12-03 | 2012-03-22 | Stem cell cultures |
HK16104657.8A HK1216883A1 (zh) | 2008-12-03 | 2016-04-22 | 幹細胞培養 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12101691.6A HK1161590A1 (en) | 2008-12-03 | 2012-02-21 | Stem cell cultures |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16104657.8A HK1216883A1 (zh) | 2008-12-03 | 2016-04-22 | 幹細胞培養 |
Country Status (15)
Country | Link |
---|---|
US (7) | US8691573B2 (xx) |
EP (7) | EP4296270A3 (xx) |
JP (6) | JP5793795B2 (xx) |
KR (1) | KR101551998B1 (xx) |
CN (2) | CN102307882B (xx) |
AU (7) | AU2009322346B2 (xx) |
BR (2) | BR122021005861B1 (xx) |
CA (3) | CA2745266C (xx) |
ES (4) | ES2489040T3 (xx) |
HK (3) | HK1161590A1 (xx) |
IL (2) | IL213205A (xx) |
PT (1) | PT3623374T (xx) |
SG (2) | SG171903A1 (xx) |
WO (1) | WO2010065721A1 (xx) |
ZA (2) | ZA201104019B (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101551998B1 (ko) | 2008-12-03 | 2015-09-09 | 더 스크립스 리서치 인스티튜트 | 줄기 세포 배양 |
CN102741394B (zh) | 2009-10-16 | 2016-05-04 | 斯克里普斯研究所 | 多能细胞的诱导 |
US9334269B2 (en) | 2010-02-17 | 2016-05-10 | Amgen Inc. | Carboxamides as inhibitors of voltage-gated sodium channels |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
DK3144319T3 (da) * | 2011-09-22 | 2019-08-05 | Ab Biolamina | Cellekultursammensætning indeholdende laminin-521 |
EP3055301B1 (en) * | 2013-10-07 | 2019-11-20 | Kadmon Corporation, LLC | (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases |
PT3114214T (pt) | 2014-03-04 | 2024-01-03 | Fate Therapeutics Inc | Métodos de reprogramação melhorados e plataformas de cultura celular |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
SG11201706041XA (en) | 2015-01-26 | 2017-08-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
JP7263005B2 (ja) | 2015-10-16 | 2023-04-24 | フェイト セラピューティクス,インコーポレイテッド | 基底状態の多能性の誘導及び維持に関するプラットフォーム |
JP2018533363A (ja) | 2015-11-04 | 2018-11-15 | フェイト セラピューティクス,インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
ES2953925T3 (es) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11203576B2 (en) * | 2016-03-11 | 2021-12-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease |
CN106632057B (zh) * | 2016-08-23 | 2019-06-25 | 中国农业科学院兰州畜牧与兽药研究所 | 一种离子液体及利用其合成Thiazovivin的方法 |
US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
JP7477983B2 (ja) | 2020-02-12 | 2024-05-02 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
WO2022234965A1 (ko) * | 2021-05-07 | 2022-11-10 | 주식회사 보로노이 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
WO2023233339A1 (en) | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
WO2023240248A2 (en) | 2022-06-09 | 2023-12-14 | Umoja Biopharma, Inc. | Compositions and methods for nk cell differentiation |
WO2024026391A1 (en) | 2022-07-27 | 2024-02-01 | Umoja Biopharma, Inc. | Differentiation of stem cells in suspension culture |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
EP0257275A3 (en) * | 1986-07-28 | 1990-05-23 | American Cyanamid Company | Cephalosporin and penicillin derivatives |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
US6185506B1 (en) | 1996-01-26 | 2001-02-06 | Tripos, Inc. | Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors |
WO1998017299A1 (en) | 1996-10-18 | 1998-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase c, methods and compositions |
SE511957C2 (sv) | 1996-12-06 | 1999-12-20 | Ericsson Telefon Ab L M | Broadcasting över ATM |
US6399334B1 (en) | 1997-09-24 | 2002-06-04 | Invitrogen Corporation | Normalized nucleic acid libraries and methods of production thereof |
SI0928790T1 (en) * | 1998-01-02 | 2003-06-30 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
EP2241541A1 (en) | 1998-01-05 | 2010-10-20 | Neogenesis, Inc. | Method for identifying a member of a mass-coded combinatorial library |
US6841347B1 (en) | 1998-02-05 | 2005-01-11 | The General Hospital Corporation | In vivo construction of DNA libraries |
US6541211B1 (en) | 1998-05-20 | 2003-04-01 | Selectide Corporation | Apparatus and method for synthesizing combinational libraries |
WO2001030778A1 (en) * | 1999-10-27 | 2001-05-03 | Novartis Ag | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
MXPA02009185A (es) | 2000-03-22 | 2003-05-23 | Cellemetry Llc | Metodo y aparato para registrar la ubicacion electronica de un aparato movil de comunicaciones celulares. |
US6828098B2 (en) | 2000-05-20 | 2004-12-07 | The Regents Of The University Of Michigan | Method of producing a DNA library using positional amplification based on the use of adaptors and nick translation |
MXPA02011974A (es) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Derivados de quinazolina sustituidos y su uso como inhibidores. |
JP3777158B2 (ja) | 2000-11-10 | 2006-05-24 | アミコージェン・インコーポレイテッド | 一方向性の一本鎖dna切片を用いた組換えdnaライブラリーの製造方法 |
US20020132823A1 (en) * | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
DE60209736T2 (de) | 2001-07-02 | 2006-11-02 | Astrazeneca Ab | Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen |
HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
WO2004072068A1 (en) * | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
NZ551027A (en) * | 2004-04-08 | 2011-01-28 | Targegen Inc | Benzotriazine inhibitors of kinases |
EP1954696B1 (en) * | 2005-01-19 | 2011-02-23 | Bristol-Myers Squibb Company | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
US20060247250A1 (en) * | 2005-03-16 | 2006-11-02 | Targegen, Inc. | Pyrimidine inhibitors of kinases |
CN101563336A (zh) | 2006-03-16 | 2009-10-21 | 诺瓦提斯公司 | 用于治疗特别是黑素瘤的杂环有机化合物 |
MX2008013400A (es) * | 2006-04-19 | 2008-11-10 | Astellas Pharma Inc | Derivado de azolcarboxamida. |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
CN101563449A (zh) * | 2006-09-22 | 2009-10-21 | 理化学研究所 | 干细胞培养基及干细胞培养方法 |
JP5103604B2 (ja) * | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての2−アミノチアゾール−4−カルボン酸アミド |
US20080182328A1 (en) * | 2006-12-19 | 2008-07-31 | The Burnham Institute | Mammalian extraembryonic endoderm cells and methods of isolation |
PT2368555T (pt) | 2007-01-31 | 2016-07-25 | Biosuccess Biotech Company | Composições e métodos de utilização de ésteres de forbol |
US7838889B2 (en) | 2007-08-10 | 2010-11-23 | Eastman Kodak Company | Solid-state area illumination system |
AU2008314922B2 (en) * | 2007-10-24 | 2013-08-29 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
EP2303881A2 (en) * | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
WO2010012793A1 (en) * | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide aminothiazole derivatives |
KR101551998B1 (ko) | 2008-12-03 | 2015-09-09 | 더 스크립스 리서치 인스티튜트 | 줄기 세포 배양 |
US8004201B2 (en) * | 2009-03-06 | 2011-08-23 | Himax Analogic, Inc. | LED circuit |
TWI552751B (zh) | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法 |
-
2009
- 2009-12-03 KR KR1020117015337A patent/KR101551998B1/ko active IP Right Grant
- 2009-12-03 CA CA2745266A patent/CA2745266C/en active Active
- 2009-12-03 SG SG2011040003A patent/SG171903A1/en unknown
- 2009-12-03 JP JP2011539689A patent/JP5793795B2/ja active Active
- 2009-12-03 EP EP23207671.1A patent/EP4296270A3/en active Pending
- 2009-12-03 SG SG2014000269A patent/SG196784A1/en unknown
- 2009-12-03 US US13/132,379 patent/US8691573B2/en active Active
- 2009-12-03 EP EP16174428.9A patent/EP3103804B1/en active Active
- 2009-12-03 BR BR122021005861-0A patent/BR122021005861B1/pt active IP Right Grant
- 2009-12-03 CN CN200980156028.1A patent/CN102307882B/zh active Active
- 2009-12-03 EP EP14175853.2A patent/EP2789618B1/en active Active
- 2009-12-03 WO PCT/US2009/066554 patent/WO2010065721A1/en active Application Filing
- 2009-12-03 EP EP19205703.2A patent/EP3623374B1/en active Active
- 2009-12-03 CA CA3128456A patent/CA3128456A1/en active Pending
- 2009-12-03 EP EP21189950.5A patent/EP3936508B1/en active Active
- 2009-12-03 EP EP09831108.7A patent/EP2370445B1/en active Active
- 2009-12-03 EP EP18196634.2A patent/EP3441394B1/en active Active
- 2009-12-03 ES ES09831108.7T patent/ES2489040T3/es active Active
- 2009-12-03 ES ES18196634T patent/ES2779001T3/es active Active
- 2009-12-03 ES ES16174428T patent/ES2712074T3/es active Active
- 2009-12-03 CN CN201510256027.1A patent/CN105001196B/zh active Active
- 2009-12-03 BR BRPI0922345-2A patent/BRPI0922345B1/pt active IP Right Grant
- 2009-12-03 PT PT192057032T patent/PT3623374T/pt unknown
- 2009-12-03 ES ES19205703T patent/ES2898303T3/es active Active
- 2009-12-03 CA CA2995883A patent/CA2995883C/en active Active
- 2009-12-03 AU AU2009322346A patent/AU2009322346B2/en active Active
-
2011
- 2011-05-29 IL IL213205A patent/IL213205A/en active IP Right Grant
- 2011-05-31 ZA ZA2011/04019A patent/ZA201104019B/en unknown
- 2011-06-01 US US13/150,933 patent/US8044201B2/en active Active
-
2012
- 2012-02-21 HK HK12101691.6A patent/HK1161590A1/xx unknown
- 2012-03-22 HK HK12102882.3A patent/HK1162488A1/xx unknown
- 2012-08-14 ZA ZA2012/06083A patent/ZA201206083B/en unknown
-
2013
- 2013-10-10 IL IL228818A patent/IL228818A/en active IP Right Grant
-
2014
- 2014-02-24 US US14/188,616 patent/US9340525B2/en active Active
-
2015
- 2015-07-22 JP JP2015144532A patent/JP6127092B2/ja active Active
- 2015-09-23 AU AU2015230747A patent/AU2015230747B2/en active Active
-
2016
- 2016-04-14 US US15/098,546 patent/US9896655B2/en active Active
- 2016-04-22 HK HK16104657.8A patent/HK1216883A1/zh unknown
-
2017
- 2017-02-01 AU AU2017200667A patent/AU2017200667B2/en active Active
- 2017-04-10 JP JP2017077236A patent/JP6476398B2/ja active Active
-
2018
- 2018-01-05 US US15/863,501 patent/US10351822B2/en active Active
- 2018-05-03 AU AU2018203091A patent/AU2018203091B2/en active Active
- 2018-12-26 JP JP2018242072A patent/JP6860544B2/ja active Active
-
2019
- 2019-06-04 US US16/431,643 patent/US10975352B2/en active Active
- 2019-07-30 AU AU2019210531A patent/AU2019210531B2/en active Active
-
2021
- 2021-03-08 US US17/195,385 patent/US20210403862A1/en active Pending
- 2021-03-25 JP JP2021050945A patent/JP7256218B2/ja active Active
- 2021-07-01 AU AU2021204635A patent/AU2021204635B2/en active Active
-
2023
- 2023-03-30 JP JP2023054562A patent/JP2023073420A/ja active Pending
- 2023-10-17 AU AU2023251440A patent/AU2023251440A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216883A1 (zh) | 幹細胞培養 | |
HK1246827A1 (zh) | 細胞培養方法 | |
EP2315829A4 (en) | INDUCED PLURIPOTENT STEM CELLS | |
GB2458863B (en) | Improved culture of stem cells | |
SG10201500674YA (en) | Pluripotent stem cells | |
EP2414510A4 (en) | INDUCED PLURIPOTENT STEM CELLS | |
IL214798A0 (en) | Methods and compositions for stem cell cultures | |
IL247310B (en) | Mesenchymal stem cell differentiation | |
PL2046946T3 (pl) | Hodowla pluripotencjalnych komórek macierzystych | |
ZA201000715B (en) | Single pluripotent stem cell culture | |
GB0814249D0 (en) | Uses of mesenchymal stem cells | |
ZA201202939B (en) | Whole cell biocatalyst | |
EP2294182A4 (en) | CULTS OF MULTIPOTENT STEM CELLS | |
EP2331676A4 (en) | GROWTH FACTOR OF A HEMATOPOIETIC STEM CELL | |
GB0919773D0 (en) | Induced pluripotent stem cell | |
GB0818256D0 (en) | stem cells | |
GB0901069D0 (en) | Stem cell culture methods | |
GB0916476D0 (en) | Stem cell culture methods | |
GB0918471D0 (en) | Stem cells | |
GB0808778D0 (en) | Cell culture technique | |
GB0922428D0 (en) | Cell culture | |
GB0915268D0 (en) | Cell culture |